Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit

Key clinical point: Omecamtiv mecarbil safely met its efficacy goal in its pivotal trial in patients with heart failure with reduced ejection fraction.

Major finding: Treatment with omecamtiv mecarbil cut the primary endpoint by a significant 8% relative to placebo.

Study details: GALACTIC-HF enrolled 8,256 patients with HFrEF in an international pivotal trial.

Disclosures: GALACTIC-HF was sponsored by Amgen, Cytokinetics, and Servier, the companies developing omecamtiv mecarbil. Dr. Teerlink has received research support from and been a consultant to Amgen, Cytokinetics, and Servier, as well as Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Merck, and Novartis. Dr. Heidenreich had no disclosures. Dr. Mann is on a steering committee for a trial sponsored by Novartis and has no other commercial disclosures. Dr. Lewis is principal investigator for a trial of omecamtiv mecarbil and has no other commercial disclosures.